Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514089 | 0.87 | KMT2A (0.68) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL299233 | 0.81 | ALDH1A1 (0.60) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2093676 | 0.81 | ALDH1A1 (0.51) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2090046 | 0.81 | L3MBTL1 (0.43) | KMT2AL3MBTL1ALDH1A1POLBLMNA | |
| SCHEMBL6850954 | 0.81 | ALDH1A1 (0.71) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4554983 | 0.81 | POLB (0.77) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL31040567 | 0.81 | POLB (0.77) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL171580 | 0.79 | KMT2A (0.70) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2093160 | 0.79 | ALDH1A1 (0.62) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2755842 | 0.79 | ALDH1A1 (0.77) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | claimed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | claimed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | disclosed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102521-A1 | Excitatory amino acid receptor modulators | GRM1, GRM2, GRIN1 | KMT2A 1257/4885L3MBTL1 2983/4885ALDH1A1 1907/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | KMT2A 3324/4885L3MBTL1 2575/4885ALDH1A1 412/4885 |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | KMT2A 1766/4885L3MBTL1 118/4885ALDH1A1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.